Neurology Search
Neurology Neurology
myasthenia%20gravis
MYASTHENIA GRAVIS
Myasthenia gravis is an autoimmune neurological disorder caused by autoantibodies against the acetylcholine receptor or against a receptor-associated protein, muscle-specific tyrosine kinase (MuSK-Ab).
The autoimmune attack at the muscle endplate leads to failure of neuromuscular transmission and eventually muscle weakness.
In the active phase of the disease, symptoms typically fluctuates and then become severe; myasthenic crisis occur in this phase.
In the stable/inactive phase, symptoms are stable but still persist; it usually worsen attributable to infection, fatigue, tapering of medications or other identifiable factors.
In the burnt-out phase, remission may occur wherein patients are on immunotherapy and symptom-free, or may even be off medications.
In 15-20 years, if the symptoms left untreated, patient's weakness becomes fixed wherein the most severely affected muscles become atrophic.

Surgical Intervention

Thymectomy

  • No consensus is in place on which surgical method is first line
  • Based on a study, more severe cases of myasthenia gravis may benefit from thymectomy compared to patients with mild myasthenia gravis
  • It is advisable that the patient be stabilized with immunotherapy before undergoing thymectomy to reduce perioperative morbidity & mortality
  • Patients with acetylcholine receptor antibody-positive early-onset generalized myasthenia gravis with insufficient response to pyridostigmine therapy are candidates for thymectomy
  • Video-assisted thoracoscopic surgery (VATS) may be considered in preference to the transsternal approach
  • Many papers demonstrate superior results of VATS in terms of hospital stay, operative blood loss & patient satisfaction compared to the transsternal approach

Presence of Thymoma

  • If patient has a thymoma it is highly recommended that the patient undergo early total thymectomy to prevent local tumor spread (although most tumors are benign)
    • Tumor & adherent structures should be completely removed
    • Chest cavity should be inspected for tumor implants
  • 66% of patients with myasthenia gravis  & nonmalignant thymoma were found to be symptom-free at 6 months-7 years after thymectomy & treatment with Prednisolone &/or Azathioprine therapy

Non-Thymomatous Autoimmune Myasthenia Gravis

  • Thymectomy in the absence of tumor offers possibility of long-term benefit for those with generalized myasthenia gravis & anti-AChR antibodies
    • It may increase the probability of improvement or drug-free remission
  • Studies showing improvement have conflicting differences in baseline characteristics of prognostic factors & confounding variables (eg age, severity of myasthenia gravis)
    • Regardless, most studies have found improvement or myasthenia gravis remission in patients undergoing thymectomy
    • Improvement is slow & may take months-years

Ophthalmic Surgery

  • For correction of ptosis &/or diplopia
Editor's Recommendations
Most Read Articles
Product Highlight - ADACEL
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Spotlight on multidrug-resistant gram-negative infections: New developments for an old problem
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
IBD: Where there’s smoke, there’s colorectal neoplasia
Jairia Dela Cruz, 6 days ago
For inflammatory bowel disease (IBD) patients, smoking cigarettes or just being exposed to secondhand smoke raises the risk of developing colorectal neoplasia, a study has found.
Standing good for heart health
Jairia Dela Cruz, 2 days ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.